3192

Actin Binding Peptides from T2 RNase (hRNASET2) as Angiogenesis Agents for the Treatment of Cancer

Shoseyov Oded, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Plant Sciences and Genetics
FRIEDLER Assaf, HUJI, Faculty of Science, The Institute of Chemistry
Schwartz Betty, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Biochemistry, Food Science and Nutrition
AMARTELY Hadar, HUJI, Faculty of Science, The Institute of Chemistry
NESIEL Liron, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Plant Sciences and Genetics
DORON Shani, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Plant Sciences and Genetics

Category

LifeSciences and BioTechnology   

Current development stage

TRL3 - hypothesis testing and initial POC demonstrated in limited # of in-vitro models

Our Innovation

  • We demonstrated that recombinant human T2 RNase could inhibit tumor growth, tumorigenesis metastatic transformation and metastatic spread, and effectively bind actin in both cell-free systems and on the surface of cancer cells in culture.
  • It was proven that Angiogenic-related inhibition is completely dependent on the peptide’s ability to bind actin.

Application

Due to its antiangiogenic and antitumorigenic activities, RNASET2 was suggested to inhibit cell motility by binding to actin. Therefore, the identification of the actin-binding sequence of the hRNASET2, could contribute to design of  anti-cancer peptide drugs based on the hNase T2.

Opportunity

Short peptide based drugs will be easier and more cost effective than a parallel protein drugs. Since such peptides are derived from human protein, it is likely that it will not be immunogenic. Peptides could be produced in large amount and could be administered orally when combined in appropriate orally administration delivery system/s.  Reduction of production costs and predicted reduced side effects will allow chronic treatment to ensure treatment success while keeping patients quality of life.

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608